Quality indicators and technique for analyzing permanent I-125 prostate seed implants: Seven years postimplant dosimetry evaluation

被引:6
|
作者
Marcu, Loredana G. [1 ,2 ,3 ]
Lawson, John M. [1 ]
Rutten, Thomas [1 ]
Gowda, Raghu [4 ]
机构
[1] Royal Adelaide Hosp, Dept Med Phys, Adelaide, SA 5000, Australia
[2] Univ Oradea, Fac Sci, Oradea 10087, Romania
[3] Univ Adelaide, Sch Chem & Phys, Adelaide, SA 5000, Australia
[4] Royal Adelaide Hosp, Dept Radiat Oncol, Adelaide, SA 5000, Australia
关键词
image fusion; dose volume histogram; natural dose ratio; low dose rate brachytherapy; organs at risk; ESTRO/EAU/EORTC RECOMMENDATIONS; BRACHYTHERAPY; CANCER; IMPACT; MONOTHERAPY; EXPERIENCE; VOLUMES; EDEMA;
D O I
10.1118/1.4725173
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The roles of postimplant dosimetry (PID) after permanent I-125 implant are to identify and rectify inadequate implants, assess the dosimetric quality indicators, and evaluate dose to the organs at risk. The aim of the current work was to assess the progress of prostate implant quality via postimplant dosimetry over seven years. Methods: The following factors were investigated to assess the PID results obtained over seven years: the improvement in implant technique, the computed tomography (CT) delineation-based PID versus ultrasound-CT (US-CT) fusion-based PID, and the evolution of parameters such as D90 and NDR (natural dose ratio). The correlation between dosimetric parameters and clinical outcomes were also evaluated. Results: The seven years PID learning curve shows clear changes in dosimetric trend for the 265 patients studied. Manual target contouring on CT was shown to overestimate the prostate volume when compared to ultrasound data, translating to CT-based D90 values being lower than US-CT D90. It was found that NDR does not contribute with additional dosimetric information to postimplant dosimetry evaluation. Patient follow-up data show that 4.7% patients have relapsed, and urinary retention was reported in 2.7% of the patients. Conclusions: CT-based PID was found less reliable than US-CT fusion-based PID due to target volume overestimation. This result shows the biased interpretation of low D90 values based on CT-based targeting, providing unreliable correlations between D90 and relapse probability. The low urinary retention statistics are in accordance with the PID data for the organ, as only 5.2% of patients had their PID D10 > 218 Gy, i.e., above the recommended GEC-ESTRO guidelines. Besides the "learning" component, the PID D90 curve is influenced by the PID technique. (C) 2012 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4725173]
引用
收藏
页码:4123 / 4131
页数:9
相关论文
共 50 条
  • [1] Is the V150 a good quality indicator of postimplant dosimetry for I-125 permanent prostate brachytherapy?
    Zarza Moreno, M.
    Carita, L.
    Antunes, T.
    Fortunato, M.
    Rebola, J.
    Roldao, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S334 - S335
  • [2] Development of method to visualize I-125 seed in postimplant seed identification in prostate permanent implant brachytherapy.
    Takahashi, Y.
    Sumida, I.
    Kozuka, T.
    Ito, A.
    Yamashita, T.
    [J]. MEDICAL PHYSICS, 2006, 33 (06) : 2086 - 2086
  • [3] Prostate brachytherapy with permanent I-125 seed implants -: first experiences at the KSSG
    Töpfer, M
    Prikler, L
    Seelentag, W
    Ries, G
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 : 121 - 121
  • [4] Post implant dosimetric evaluation of I-125 permanent prostate implants
    Kota, C
    Yudelev, M
    Chungbin, S
    Litrrup, P
    Wood, D
    Forman, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 346 - 346
  • [5] Use of sector analysis of I-125 permanent prostate brachytherapy to evaluate and compare pre- and postimplant dosimetry
    Yoosuf, Ahamed Badusha Mohamed
    Workman, Geraldine
    O'Toole, Monica M.
    Straney, Margaret
    Verghis, Rejina
    Napier, Eoin
    Mitchell, Darren M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [6] Comparison of 3 different postimplant dosimetry methods following permanent 125I prostate seed brachytherapy
    Marcu, Loredana G.
    Gowda, Raghu
    [J]. MEDICAL DOSIMETRY, 2013, 38 (03) : 309 - 314
  • [7] Postimplant dosimetry for 125I prostate implants:: Definitions and factors affecting outcome
    Stock, RG
    Stone, NN
    Lo, YC
    Malhado, N
    Kao, J
    DeWyngaert, JK
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 899 - 906
  • [8] Preliminary study of correction of original metal artifacts due to I-125 seeds in postimplant dosimetry for prostate permanent implant brachytherapy
    Takahashi Y.
    Mori S.
    Kozuka T.
    Gomi K.
    Nose T.
    Tahara T.
    Oguchi M.
    Yamashita T.
    [J]. Radiation Medicine, 2006, 24 (2): : 133 - 138
  • [9] Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging
    Moerland, MA
    Wijrdeman, HK
    Beersma, R
    Bakker, CJG
    Battermann, JJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (04): : 927 - 933
  • [10] Dosimetric consequences of increased seed strength for I-125 prostate implants
    Sloboda, RS
    Pedersen, JE
    Hanson, J
    Halperin, RM
    [J]. RADIOTHERAPY AND ONCOLOGY, 2003, 68 (03) : 295 - 297